Latest news with #Psoriasis
Medscape
14-07-2025
- Health
- Medscape
GRAPPA 2025
July 10 - 12, 2025; Bogotá, Colombia GRAPPA 2024 GRAPPA 2023 GRAPPA 2022 Psoriasis Psoriatic Arthritis
Medical News Today
09-07-2025
- Health
- Medical News Today
Foods to avoid while receiving Stelara
Stelara has no known food interactions, but diet is still an important part of symptom management for the conditions the drug is a brand-name drug that doctors prescribe to treat certain autoimmune conditions, including:plaque psoriasis in certain adults and children ages 6 years and olderpsoriatic arthritis in adults and children ages 6 years and olderCrohn's disease in adultsulcerative colitis in adultsWhile Stelara doesn't interact with any foods, certain foods may affect the conditions Stelara treats or help with the drug's side effects.»Learn more about Stelara, including it's uses and to avoid while receiving StelaraThere are no reports of Stelara interacting with certain foods and beverages can increase inflammation in your body. This can trigger symptoms of the conditions you're receiving Stelara to treat. Examples of these foods and beverages include:Processed foods: Processed foods, such as prepackaged snacks or meals, link to a higher risk of autoimmune foods: A 2023 research review showed a link between sugar consumption and psoriasis flare-ups. A diet high in sugary foods, such as candy, cookies, cake, and drinks, is likely to worsen symptoms of conditions caused by or fatty foods: Foods high in saturated and trans fat, such as fried foods, processed snacks, and fatty meats, can also increase While there's no interaction between alcohol and Stelara, alcohol may worsen symptoms of the condition you're receiving Stelara to treat.»Learn more about drugs and vaccines that interact with tips for managing the side effects of StelaraSome common side effects reported in Stelara's studies include:nauseavomitingabdominal paindiarrheaAvoiding or eating certain foods may help with managing these side example, if you're experiencing diarrhea, eating foods high in soluble fiber, such as bananas, oatmeal, and rice, may be helpful to thicken the stool. On the other hand, it may be best to limit creamy, fried, high dairy, and sugary foods, as these can worsen you're experiencing vomiting while receiving Stelara, eating smaller meals throughout the day, instead of three large meals, may be helpful. You also may want to avoid spicy hydrated is also important to help manage these digestive side you have questions about managing Stelara's side effects, talk with your doctor or pharmacist.»Learn more about side effects of Stelara doesn't interact with food, certain foods, including sugary foods, may increase the risk of symptoms of the condition you're receiving the drug to may also need to avoid or eat certain foods to help manage the digestive side effects of with your doctor or pharmacist if you have questions about foods and Stelara.
&w=3840&q=100)
Business Standard
04-06-2025
- Business
- Business Standard
Sun Pharma Advanced Research hits 20% lower band; what's rattling Street?
Sun Pharma Advanced Research Company (SPARC) shares slumped 20 per cent in trade on Wednesday, June 4, 2025, hitting its lower circuit at ₹156.5 per share on BSE. The stock was under pressure after the company's partner Sun Pharmaceutical Industries informed that its phase 2 trial for evaluating SOLARES PsO and SOLARES AD studies failed to meet the primary endpoint. In the past one year, Sun Pharma Advanced Research Company shares have declined 3 per cent as compared to Sensex's rise of around 12 per cent. At 9:36 AM, Sun Pharma Advanced Research share price was down 15.16 per cent at ₹165.95 per share on the BSE. In comparison, the BSE Sensex was up 0.04 per cent at 80,766.66. The market capitalisation of the company stood at ₹5,385.44 crore. The 52-week high of the stock was at ₹257.7 per share and the 52-week low of the stock was at ₹109.2 per share. Why did Sun Pharma Advanced Research stock tanked? The company released a filing on Tuesday, after market hours, in which it said that the phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD) failed to meet primary endpoint of 75 per cent improvement in Psoriasis Area and Severity Index (PASI). "SPARC informs that its partner Sun Pharmaceutical Industries Limited (SPIL) announced the top-line results from the Phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD). SPIL informed that both SOLARES PsO and SOLARES AD studies did not meet the primary endpoint of 75 per cent improvement in PASI (Psoriasis Area and Severity Index) score (> PASI75) at Week 16 and 75 per cent improvement in EASI (Eczema Area and Severity Index) score (>EASI75) at Week 16 respectively," the filing read. It added: SPARC and SPIL will evaluate the appropriate next steps for SCD-044. Psoriasis is a chronic autoimmune condition characterised by skin inflammation and accelerated skin cell growth, resulting in raised, scaly patches called plaques, most commonly on the elbows, knees, scalp, and trunk. Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterised by dry, itchy, and inflamed skin. It's a long-term condition that can cause patchy rashes and can occur at any age, though it often begins in childhood.
Time of India
04-06-2025
- Business
- Time of India
Sun Pharma Advanced Research shares tank 20% after psoriasis drug fails Phase 2 trials
Shares of Sun Pharma Advanced Research Company (SPARC), a unit of India's largest drug maker Sun Pharmaceutical Industries , tumbled as much as 20% on Wednesday to Rs 156.50 on the BSE after the company disclosed that its investigational drug SCD-044 failed to meet the main goals in late-stage clinical trials for psoriasis and atopic dermatitis. In a filing released post-market hours on Tuesday, SPARC said, 'SPARC informs that its partner Sun Pharmaceutical Industries Limited (SPIL) announced the top-line results from the Phase 2 clinical trials evaluating Vibozilimod (SCD-044) for the treatment of moderate-to-severe Psoriasis (SOLARES PsO) and Atopic Dermatitis (SOLARES AD)." "SPIL informed that both SOLARES PsO and SOLARES AD studies did not meet the primary endpoint of 75 per cent improvement in PASI (Psoriasis Area and Severity Index) score (> PASI75) at Week 16 and 75 per cent improvement in EASI (Eczema Area and Severity Index) score (>EASI75) at Week 16, respectively,' the company said. The company further added, 'SPARC and SPIL will evaluate the appropriate next steps for SCD-044.' SPARC confirmed that, given the failure to meet primary endpoints, the development of the drug, also known as Vibozilimod, is being discontinued, and no further clinical trials are planned. The setback is significant as the drug was seen as a key asset in the company's speciality pipeline. Also read: Flipkart exits Aditya Birla Fashion and Retail in Rs 582 crore bulk deal; ABFRL stock tumbles 11% Over the past year, SPARC shares have declined about 3%, underperforming the benchmark Sensex, which has risen roughly 12% during the same period. Surprise FDA inspection at Halol unit Separately, CNBC-TV18 reported on Wednesday that a surprise inspection was underway at Sun Pharma's Halol facility, one of its largest manufacturing units, by three inspectors from the U.S. Food and Drug Administration. The Halol unit was last inspected in May 2022 and is currently under an import alert following a warning letter from the regulator. Also read | Sensex will hit 1.5 lakh by 2030 & 3 lakh by 2035! Raamdeo Agrawal makes big prediction About the drug and its target conditions Vibozilimod was being developed as a treatment for psoriasis and atopic dermatitis, two chronic inflammatory skin conditions. Psoriasis is marked by raised, scaly plaques on the skin due to accelerated skin cell growth, often affecting the elbows, knees, scalp, and trunk. Atopic dermatitis, or eczema, typically involves dry, itchy, and inflamed skin, often beginning in childhood but potentially affecting people at any age. The failure of the Phase 2 studies now casts uncertainty over SPARC's speciality drug pipeline, with investors and analysts awaiting further clarity on the company's next steps. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
Zawya
01-06-2025
- Business
- Zawya
Novartis and Kuwait Society of Dermatologists enter strategic partnership to advance dermatological care in Kuwait
Under the title 'United for Dermatology', the partnership will drive awareness, disease understanding, and improve the lives of patients in Kuwait diagnosed with Psoriasis, Hidradenitis Suppurativa & Chronic Spontaneous Urticaria Kuwait City, Kuwait – Novartis, a global leader in innovative medicines, signed a partnership agreement with the Kuwait Society of Dermatologists, focused on transforming dermatological care in Kuwait. This strategic partnership will prioritize high-impact immunological skin conditions such as Psoriasis, Hidradenitis Suppurativa (HS) and Chronic Spontaneous Urticaria (CSU) with a shared goal of bridging diagnostic gaps and improving the quality of life for patients. Together, Psoriasis, Hidradenitis Suppurativa (HS), and Chronic Spontaneous Urticaria (CSU) represent distinct chronic inflammatory skin diseases, each with unique clinical presentations and significant impact on quality of life. Beyond physical symptoms, conditions like Psoriasis, Hidradenitis Suppurativa and CSU often take a significant toll on patients' mental health, contributing to anxiety, depression and social isolation—underscoring the importance of timely, compassionate and comprehensive care. This partnership is focused on increasing education and disease awareness within the public and HCPs, in addition to evidence-driven solutions that ensure faster, more accurate diagnoses and better treatment outcomes. Dr. Atlal Allafi, President, Kuwait Society of Dermatologists, said, 'Our partnership with Novartis is focused on breaking down barriers to care. Together, we're working to empower patients to recognize symptoms earlier and support physicians in identifying these conditions sooner. By accelerating diagnosis and access to treatment, we aim to enhance patient outcomes and overall well-being.' Rabab Monir, Country Operations Head - Kuwait, Novartis, added, 'Driven by our mission to transform the future of medicine, Novartis is proud to join forces with the Kuwait Society of Dermatologists to elevate dermatological care across Kuwait. Through this collaboration, we're fostering a healthcare environment where early intervention and personalized treatment pave the way for improved patient outcomes.' A professional organization for dermatologists in Kuwait, the Kuwait Society of Dermatologists is dedicated to advancing dermatological care through education, research, and public awareness. Committed to the highest standards of medical ethics and excellence, the society plays a key role in promoting skin health across the nation. Dr Abeer Albazali, Vice President, Kuwait Society of Dermatologists, commented, 'We aim to foster collaboration among dermatologists, encouraging the exchange of knowledge and best practices that drive progress in patient care. This partnership empowers us to move from dialogue to delivery—bringing global breakthroughs to life through locally tailored solutions.' Through this collaboration, Novartis and the Kuwait Society of Dermatologists reinforce their mutual commitment to a future where patients benefit from early diagnosis, individualized care, and an improved quality of life. Disease Descriptors Chronic Spontaneous Urticaria (CSU) is a medical condition that affects 0.5-1 per cent of the global population and is characterized by chronic hives that last for six weeks or longer. These hives can appear without an obvious trigger and may cause significant itching and discomfort. Hidradenitis Suppurativa (HS) is a chronic skin condition more common in women and often undiagnosed, marked by recurrent, painful lumps or nodules under the skin. These lesions often become inflamed, can rupture, and may lead to scarring over time. Psoriasis is a chronic autoimmune skin disorder characterized by thick, red, scaly plaques on the skin. These lesions can be itchy, painful, and sometimes extensive. It is estimated that between 1 and 3 per cent of the population across countries in the Gulf are affected by this condition. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Reimagine medicine with us: Visit us at and connect with us on LinkedIn, Facebook, X/Twitter and Instagram.
